209 related articles for article (PubMed ID: 32139796)
1. Transcriptomic signatures of brain regional vulnerability to Parkinson's disease.
Keo A; Mahfouz A; Ingrassia AMT; Meneboo JP; Villenet C; Mutez E; Comptdaer T; Lelieveldt BPF; Figeac M; Chartier-Harlin MC; van de Berg WDJ; van Hilten JJ; Reinders MJT
Commun Biol; 2020 Mar; 3(1):101. PubMed ID: 32139796
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic profiling of Parkinson's disease brains reveals disease stage specific gene expression changes.
Cappelletti C; Henriksen SP; Geut H; Rozemuller AJM; van de Berg WDJ; Pihlstrøm L; Toft M
Acta Neuropathol; 2023 Aug; 146(2):227-244. PubMed ID: 37347276
[TBL] [Abstract][Full Text] [Related]
3. Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease.
Thomas GEC; Zarkali A; Ryten M; Shmueli K; Gil-Martinez AL; Leyland LA; McColgan P; Acosta-Cabronero J; Lees AJ; Weil RS
Brain; 2021 Jul; 144(6):1787-1798. PubMed ID: 33704443
[TBL] [Abstract][Full Text] [Related]
4. Review: Clinical, neuropathological and genetic features of Lewy body dementias.
Hansen D; Ling H; Lashley T; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2019 Dec; 45(7):635-654. PubMed ID: 30977926
[TBL] [Abstract][Full Text] [Related]
5. Is Braak staging valid for all types of Parkinson's disease?
Jellinger KA
J Neural Transm (Vienna); 2019 Apr; 126(4):423-431. PubMed ID: 29943229
[TBL] [Abstract][Full Text] [Related]
6. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease.
Iannaccone S; Cerami C; Alessio M; Garibotto V; Panzacchi A; Olivieri S; Gelsomino G; Moresco RM; Perani D
Parkinsonism Relat Disord; 2013 Jan; 19(1):47-52. PubMed ID: 22841687
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease susceptibility variants and severity of Lewy body pathology.
Heckman MG; Kasanuki K; Diehl NN; Koga S; Soto A; Murray ME; Dickson DW; Ross OA
Parkinsonism Relat Disord; 2017 Nov; 44():79-84. PubMed ID: 28917824
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
Halliday G; McCann H; Shepherd C
Expert Rev Neurother; 2012 Jun; 12(6):673-86. PubMed ID: 22650170
[TBL] [Abstract][Full Text] [Related]
9. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
10. The progression of pathology in Parkinson's disease.
Halliday GM; McCann H
Ann N Y Acad Sci; 2010 Jan; 1184():188-95. PubMed ID: 20146698
[TBL] [Abstract][Full Text] [Related]
11. Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study.
Nicholl DJ; Vaughan JR; Khan NL; Ho SL; Aldous DE; Lincoln S; Farrer M; Gayton JD; Davis MB; Piccini P; Daniel SE; Lennox GG; Brooks DJ; Williams AC; Wood NW
Brain; 2002 Jan; 125(Pt 1):44-57. PubMed ID: 11834592
[TBL] [Abstract][Full Text] [Related]
12. Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease.
Marsal-García L; Urbizu A; Arnaldo L; Campdelacreu J; Vilas D; Ispierto L; Gascón-Bayarri J; Reñé R; Álvarez R; Beyer K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450872
[TBL] [Abstract][Full Text] [Related]
13. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions.
Walker L; Stefanis L; Attems J
J Neurochem; 2019 Sep; 150(5):467-474. PubMed ID: 30892688
[TBL] [Abstract][Full Text] [Related]
14. Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread.
Freeze B; Pandya S; Zeighami Y; Raj A
Brain; 2019 Oct; 142(10):3072-3085. PubMed ID: 31359041
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
16. Common gene expression signatures in Parkinson's disease are driven by changes in cell composition.
Nido GS; Dick F; Toker L; Petersen K; Alves G; Tysnes OB; Jonassen I; Haugarvoll K; Tzoulis C
Acta Neuropathol Commun; 2020 Apr; 8(1):55. PubMed ID: 32317022
[TBL] [Abstract][Full Text] [Related]
17. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
Eyal A; Engelender S
Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
[TBL] [Abstract][Full Text] [Related]
18. Spreading of alpha-synuclein - relevant or epiphenomenon?
Killinger BA; Kordower JH
J Neurochem; 2019 Sep; 150(5):605-611. PubMed ID: 31152606
[TBL] [Abstract][Full Text] [Related]
19. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
